Compare · GLP-1 agonist
CagriSema vs Liraglutide
Both are glp-1 agonist compounds. Here's how they line up on the evidence — graded the same way.
| CagriSema | Liraglutide | |
|---|---|---|
| Evidence | 9/10 | 10/10 |
| Class | GLP-1 agonist | GLP-1 agonist |
| Summary | An investigational once-weekly fixed combination of cagrilintide (an amylin analog) plus semaglutide (a GLP-1 drug) with large peer-reviewed Phase 3 weight-loss data, but no approval yet and a failed head-to-head against tirzepatide. | A once-daily GLP-1 drug with large RCT support for glucose control, weight loss, and lower cardiovascular risk in high-risk type 2 diabetes. |
| Full profile → | Full profile → |
CagriSema
CagriSema is one of the most heavily studied combination products in the pipeline of new obesity drugs. It's also a good example of why "strong trial data" and "proven, approved, and better than the alternatives" are not the same thing. It's a once-weekly shot that packs two peptides into a single…
Liraglutide
Liraglutide is one of the most thoroughly studied metabolic drugs of the last fifteen years, and it's the direct predecessor to semaglutide. Its two approved uses rest on large, repeated, double-blind randomized trials (carefully controlled studies where neither patients nor doctors know who got…